Aurinia Pharmaceuticals (AUPH) Net Cash Flow (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Net Cash Flow data on file, last reported at -$39.2 million in Q1 2026.

• Quarterly Net Cash Flow fell 130.55% year-over-year to -$39.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.4 million (down 1391.01% YoY) and the FY2025 annual result came in at -$3.2 million, down 109.32% from the prior year.
• Net Cash Flow fell to -$39.2 million in Q1 2026, from $7.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $46.3 million in Q4 2024 to a low of -$99.4 million in Q1 2022.
• A 5-year average of -$11.2 million and a median of -$5.2 million in 2023 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 1768.08% in 2024, down 325.72% in 2024.
• Tracing AUPH's Net Cash Flow over 5 years: stood at $8.1 million in 2022, then tumbled by 69.48% to $2.5 million in 2023, then surged by 1768.08% to $46.3 million in 2024, then sank by 84.83% to $7.0 million in 2025, then tumbled by 658.16% to -$39.2 million in 2026.
• The last three Net Cash Flow figures came in at -$39.2 million (Q1 2026), $7.0 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.